Matching articles for "Steglatro"
Issue 1742 · November 24, 2025
Noninsulin Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is…

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):185-92 doi:10.58347/tml.2025.1742a
Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.
Issue 1742 · November 24, 2025 Free
Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (online only)

View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e191-4 doi:10.58347/tml.2025.1742b
View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Issue 1742 · November 24, 2025 Free
Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (online only)

View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e191-4 doi:10.58347/tml.2025.1742b
View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Issue 1723 · March 3, 2025
A Renal Indication for Semaglutide (Ozempic)

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):38-40 doi:10.58347/tml.2025.1723d
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). It is the first GLP-1 receptor agonist to be approved in the US for this indication.
Issue 1683 · August 21, 2023
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes

Bexagliflozin ( Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):130-2 doi:10.58347/tml.2023.1683b
Bexagliflozin ( Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication (see Table 4).
Issue 1681 · July 24, 2023
Sotagliflozin (Inpefa) for Heart Failure

The FDA has approved sotagliflozin ( Inpefa – Lexicon), an oral sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, to reduce the risk of hospitalization for heart failure (HF), urgent HF visits, and…

Med Lett Drugs Ther. 2023 Jul 24; 65(1681):114-6 doi:10.58347/tml.2023.1681b
The FDA has approved sotagliflozin ( Inpefa – Lexicon), an oral sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, to reduce the risk of hospitalization for heart failure (HF), urgent HF visits, and cardiovascular death in adults with either HF (with any left ventricular ejection fraction [LVEF]) or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is the first dual SGLT1/2 inhibitor to be approved in the US. Unlike SGLT2 inhibitors, it is not FDA-approved to improve glycemic control in adults with type 2 diabetes. Sotagliflozin is approved in the European Union as Zynquista for adjunctive treatment of type 1 diabetes.
Issue 1679 · June 26, 2023 Free
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)

The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin ( Farxiga – AstraZeneca) was approved by the FDA in 2020 to reduce the risk of cardiovascular death and hospitalization for heart failure…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):101-2 doi:10.58347/tml.2023.1679c
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin ( Farxiga – AstraZeneca) was approved by the FDA in 2020 to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF). The indication has now been expanded to include a reduction in the risk of urgent HF visits and use in adults with any left ventricular ejection fraction (LVEF).
Issue 1663 · November 14, 2022
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):177-84
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Issue 1648 · April 18, 2022 Free
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and…

Med Lett Drugs Ther. 2022 Apr 18; 64(1648):57
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF; LVEF ≤40%), regardless of whether or not they have type 2 diabetes. The indication has now been expanded to include patients with HF with any ejection fraction. Empagliflozin is the first SGLT2 inhibitor to be approved in the US for this indication.
Issue 1636 · November 1, 2021
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication

The FDA has approved an expansion of the peripheral artery disease (PAD) indication for the oral direct factor Xa inhibitor rivaroxaban ( Xarelto – Janssen) to include patients who have recently undergone a…

Med Lett Drugs Ther. 2021 Nov 1; 63(1636):172-3
The FDA has approved an expansion of the peripheral artery disease (PAD) indication for the oral direct factor Xa inhibitor rivaroxaban ( Xarelto – Janssen) to include patients who have recently undergone a lower extremity revascularization procedure for symptomatic PAD (see Table 1). Rivaroxaban is the first direct oral anticoagulant (DOAC) to be approved for use in patients with PAD.
Issue 1611 · November 16, 2020
Empagliflozin (Jardiance) for Heart Failure

In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or…

Med Lett Drugs Ther. 2020 Nov 16; 62(1611):177-8
In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the FDA for such use. The SGLT2 inhibitor dapagliflozin (Farxiga) was approved by the FDA for this indication earlier this year.
Issue 1607 · September 21, 2020 Free
In Brief: Canagliflozin and Lower Limb Amputations

The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin ( Invokana , Invokamet , Invokamet XR ) that described an…

Med Lett Drugs Ther. 2020 Sep 21; 62(1607):152
The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin ( Invokana , Invokamet , Invokamet XR ) that described an increased risk of lower limb amputation associated with use of the drug. Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation.
Issue 1584 · November 4, 2019
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can…

Med Lett Drugs Ther. 2019 Nov 4; 61(1584):169-78
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.
Issue 1545 · April 23, 2018
Ertugliflozin for Type 2 Diabetes

The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with…

Med Lett Drugs Ther. 2018 Apr 23; 60(1545):70-2
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan) . Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Issue 1513 · January 30, 2017
Comparison Table: SGLT2 Inhibitors (online only)

View the Comparison Table: SGLT2 Inhibitors

Med Lett Drugs Ther. 2017 Jan 30; 59(1513):e26
View the Comparison Table: SGLT2 Inhibitors